Advertisement
During the visit, Mr. Yanqing Liu, Chairman and CEO of China Sky OneMedical, provided an update on the advances in the Company's pipeline ofbreakthrough drugs, including the development status of a Class 1 anti-cancerclass drug. Mr. Liu also reviewed the status of the Company's applicationprocess for the National Bio-medicine Innovation Base and the NationalBreakthrough Drug Project.
Advertisement
During the visit, the Harbin government officials expressed strong supportfor and appreciation of China Sky One's R&D commitment and leadership withinHarbin's pharmaceutical industry. To encourage the Company to continue its R&Defforts, Harbin's Committee of Industry and Information plans to provide theCompany with free access to the national marketing information managementsystem. Additionally, if the Company has a new product included in theNational Breakthrough Drug Project, Harbin's Committee of Development andReform and Harbin Bureau of Science and Technology have committed to jointlyprovide government funding to help drive the Company's novel R&D programs.
"We appreciate Harbin government's support for our R&D efforts, whichreinforces the Company's commitment to continue to expand our productportfolio and develop high-value novel drugs," said Mr. Yan-Qing Liu.
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company.The Company engages in the manufacturing, marketing and distribution ofpharmaceutical, medicinal and diagnostic products. Through its wholly-ownedsubsidiaries, Harbin Tian Di Ren Medical Science and Technology Company("TDR"), Harbin First Bio-Engineering Company Limited ("First"), HeilongjiangTianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin ChuangPharmaceutical Company ("Jin Chuang") the Company manufactures and distributesover-the-counter pharmaceutical products, which make up its major revenuesource. For more information, visit http://www.cski.com.cn .
Safe Harbor Statement
Certain of the statements made in the press release constituteforward-looking statements within the meaning of the Private SecuritiesLitigation Reform Act of 1995. These statements can be identified by the useof forward- looking terminology such as "believe," "expect," "may," "will,""should," "project," "plan," "seek," "intend," or "anticipate" or the negativethereof or comparable terminology. Such statements typically involve risks anduncertainties and may include the government support and its effect on theCompany's operational results. Actual results could differ materially from theexpectations reflected in such forward-looking statements as a result of avariety of factors, including the risks associated with the ability to developnew technologies and products, market acceptance of new product launches,achievability of management's estimates of product sales, the effect ofchanging economic conditions in The People's Republic of China, variations innew product development, risks associated with rapid technological change, andthe potential of introduced or undetected flaws and defects in products, andother risk factors detailed in reports filed with the Securities and ExchangeCommission from time to time.For more information, please contact: Company Contact: China Sky One Medical, Inc. Mr. Stanley Hao, CFO Tel: +86-0451- 87032617 Email: [email protected] Investor Relations Contact: CCG Investor Relations Ms. Lei Huang, Account Manager Tel: +1-646-833-3417 Email: [email protected] Website: www.ccgirasia.com Ms. Mabel Zhang, Vice President Tel: +1-310-954-1353 Email: [email protected]
SOURCE China Sky One Medical, Inc.
